论文部分内容阅读
从１２例骨肉瘤患者手术切除的实体瘤中分离肿瘤浸润淋巴细胞（ＴＩＬ），从患者引流淋巴结中分离淋巴细胞（ＬＮＬ），以ｒＩｌ—２激活培养，并以４小时５１Ｃｒ释放试验测定ＴＩＬ和ＬＮＬ体外抗瘤活性。结果表明：１２例骨肉瘤患者的ＴＩＬ培养１５～２５天，对Ｋ５６２和ＬｉＢｒ靶细胞（效靶比２５∶１）平均杀伤活性分别为５９．７±１２．６％和４４．２±１０．２％，激活的ＬＮＬ对Ｋ５６２和ＬｉＢｒ细胞的杀伤活性分别为５５．２±１１．６％和４０．８±９．１％，二者对Ｋ５６２和ＬｉＢｒ细胞杀伤活性相差不显著（Ｐ＞０．０５）。其中６例患者ＴＩＬ和ＬＮＬ对自身肿瘤细胞杀伤活性分别为３８．８±９．５％和３５．５±７．６％，二者相差不显著（Ｐ＞０．０５）。
Tumor-infiltrating lymphocytes (TIL) were isolated from 12 solid tumors resected from patients with osteosarcoma, and lymphocytes (LNL) were isolated from patients’ draining lymph nodes. The cells were activated by rI1-2 activation and measured by 4-hour 51Cr release test. LNL antitumor activity in vitro. The results showed that: 12 cases of osteosarcoma TIL cultured 15 to 25 days, the average killing activity of K562 and LiBr target cells (Effect ratio: 25:1) were 59.7±12.6% and 44.2±10, respectively. At 2%, the killing activity of activated LNL on K562 and LiBr cells was 55.2±11.6% and 40.8±9.1%, respectively. There was no significant difference in killing activity between K562 and LiBr cells (P>0). .05). Among them, the killing activities of TIL and LNL on autologous tumor cells were 38.8±9.5% and 35.5±7.6%, respectively, and there was no significant difference between the two (P>0.05).